Now Is The Time To Build A Position In AIM ImmunoTech Inc (AMEX:AIM)

NOVA

In the latest trading session, 0.41 million AIM ImmunoTech Inc (AMEX:AIM) shares changed hands as the company’s beta touched -0.30. With the company’s most recent per share price at $0.19 changing hands around $0.0 or -2.61% at last look, the market valuation stands at $11.92M. AIM’s current price is a discount, trading about -226.32% off its 52-week high of $0.62. The share price had its 52-week low at $0.16, which suggests the last value was 15.79% up since then. When we look at AIM ImmunoTech Inc’s average trading volume, we note the 10-day average is 0.83 million shares, with the 3-month average coming to 535.90K.

Analysts gave the AIM ImmunoTech Inc (AIM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AIM as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. AIM ImmunoTech Inc’s EPS for the current quarter is expected to be -0.09.

AIM ImmunoTech Inc (AMEX:AIM) trade information

Instantly AIM was in red as seen in intraday trades today. With action -19.92%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -5.61%, with the 5-day performance at -19.92% in the red. However, in the 30-day time frame, AIM ImmunoTech Inc (AMEX:AIM) is -12.25% down. Looking at the short shares, we see there were 0.49 million shares sold at short interest cover period of 1.63 days.

AIM ImmunoTech Inc (AIM) estimates and forecasts

Data shows that the AIM ImmunoTech Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -53.27% over the past 6 months, a 50.00% in annual growth rate that is considerably higher than the industry average of 16.30%. Year-over-year growth is forecast to reach -0.99% down from the last financial year.

Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 100k. The company’s revenue for the corresponding quarters a year ago was 65k and 40k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 53.85%. The estimates for the next quarter sales put growth at -100.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 42.86%. The 2025 estimates are for AIM ImmunoTech Inc earnings to increase by 42.50%.

AIM Dividends

AIM ImmunoTech Inc is expected to release its next quarterly earnings report in February.

AIM ImmunoTech Inc (AMEX:AIM)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 8.57% of AIM ImmunoTech Inc shares while 14.07% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 15.39%. There are 14.07% institutions holding the AIM ImmunoTech Inc stock share, with ARMISTICE CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 8.2454% of the shares, roughly 4.08 million AIM shares worth $1.52 million.

VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.021% or 1.99 million shares worth $0.74 million as of 2024-06-30.

Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 1.31 shares estimated at $0.24 million under it, the former controlled 2.06% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.97% of the shares, roughly 620.23 shares worth around $0.11 million.